340 related articles for article (PubMed ID: 9294824)
1. Disposition of aerosolized liposomal amphotericin B.
Lambros MP; Bourne DW; Abbas SA; Johnson DL
J Pharm Sci; 1997 Sep; 86(9):1066-9. PubMed ID: 9294824
[TBL] [Abstract][Full Text] [Related]
2. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins.
Chakraborty KK; Naik SR
J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435
[TBL] [Abstract][Full Text] [Related]
4. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B.
Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP
J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589
[TBL] [Abstract][Full Text] [Related]
5. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models.
Andes D; Safdar N; Marchillo K; Conklin R
Antimicrob Agents Chemother; 2006 Feb; 50(2):674-84. PubMed ID: 16436726
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection.
Alsaadi M; Italia JL; Mullen AB; Ravi Kumar MN; Candlish AA; Williams RA; Shaw CD; Al Gawhari F; Coombs GH; Wiese M; Thomson AH; Puig-Sellart M; Wallace J; Sharp A; Wheeler L; Warn P; Carter KC
J Control Release; 2012 Jun; 160(3):685-91. PubMed ID: 22516093
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.
Mihara T; Kakeya H; Izumikawa K; Obata Y; Nishino T; Takazono T; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
J Infect Chemother; 2014 Feb; 20(2):104-8. PubMed ID: 24462443
[TBL] [Abstract][Full Text] [Related]
9. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
10. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies.
Chakraborty KK; Naik SR
Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary extraction and accumulation of lipid formulations of amphotericin B.
Matot I; Pizov R
Crit Care Med; 2000 Jul; 28(7):2528-32. PubMed ID: 10921589
[TBL] [Abstract][Full Text] [Related]
12. Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis.
Falk R; Grunwald J; Hoffman A; Domb AJ; Polacheck I
Antimicrob Agents Chemother; 2004 Sep; 48(9):3606-9. PubMed ID: 15328139
[TBL] [Abstract][Full Text] [Related]
13. Aerosolized liposomal amphotericin B: prediction of lung deposition, in vitro uptake and cytotoxicity.
Fauvel M; Farrugia C; Tsapis N; Gueutin C; Cabaret O; Bories C; Bretagne S; Barratt G
Int J Pharm; 2012 Oct; 436(1-2):106-10. PubMed ID: 22814222
[TBL] [Abstract][Full Text] [Related]
14. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate in humans.
Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
Antimicrob Agents Chemother; 2002 Mar; 46(3):828-33. PubMed ID: 11850268
[TBL] [Abstract][Full Text] [Related]
16. Aerosol delivery of amphotericin B desoxycholate (Fungizone) and liposomal amphotericin B (AmBisome): aerosol characteristics and in-vivo amphotericin B deposition in rats.
Ruijgrok EJ; Vulto AG; Van Etten EW
J Pharm Pharmacol; 2000 Jun; 52(6):619-27. PubMed ID: 10875537
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
Matsui S; Imai S; Yabuki M; Komuro S
Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
[TBL] [Abstract][Full Text] [Related]
18. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome).
Watanabe A; Matsumoto K; Igari H; Uesato M; Yoshida S; Nakamura Y; Morita K; Shibuya K; Matsubara H; Yoshino I; Kamei K
Int J Infect Dis; 2010 Sep; 14 Suppl 3():e220-3. PubMed ID: 19959388
[TBL] [Abstract][Full Text] [Related]
19. Long-circulating immunoliposomal amphotericin B against invasive pulmonary aspergillosis in mice.
Otsubo T; Maruyama K; Maesaki S; Miyazaki Y; Tanaka E; Takizawa T; Moribe K; Tomono K; Tashiro T; Kohno S
Antimicrob Agents Chemother; 1998 Jan; 42(1):40-4. PubMed ID: 9449258
[TBL] [Abstract][Full Text] [Related]
20. Biodistribution of liposomal amphotericin B (AmBisome) and amphotericin B-desoxycholate (Fungizone) in uninfected immunocompetent mice and leucopenic mice infected with Candida albicans.
van Etten EW; Otte-Lambillion M; van Vianen W; ten Kate MT; Bakker-Woudenberg AJ
J Antimicrob Chemother; 1995 Apr; 35(4):509-19. PubMed ID: 7628985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
